Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43865   clinical trials with a EudraCT protocol, of which   7286   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-004844-20
    Sponsor's Protocol Code Number:ADXS001-02
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2017-02-23
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2015-004844-20
    A.3Full title of the trial
    Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV (Advaxis IMmunotherapy 2 prevent CERVical recurrence)
    Estudio de fase III de ADXS11-001 administrado tras la quimiorradioterapia como tratamiento adyuvante en cáncer de cuello uterino localmente avanzado de riesgo alto: AIM2CERV
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer (AIM2CERV)
    Estudio de ADXS11-001 en sujetos con cáncer de cuello uterino localmente avanzado de riesgo alto (AIM2CERV).
    A.4.1Sponsor's protocol code numberADXS001-02
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT02853604
    A.5.4Other Identifiers
    Name:IND numberNumber:013712
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAdvaxis, Inc
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAdvaxis, Inc 305 College Road East Princeton, NJ 08540
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAdvaxis, Inc
    B.5.2Functional name of contact pointRegulatory Affairs
    B.5.3 Address:
    B.5.3.1Street Address305 College Road East
    B.5.3.2Town/ cityPrinceton
    B.5.3.3Post codeNJ 08540
    B.5.3.4CountryUnited States
    B.5.4Telephone number+3491 4322630
    B.5.5Fax number+1609-452-9818
    B.5.6E-maildu@advaxis.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameADXS11-001
    D.3.2Product code ADXS11-001
    D.3.4Pharmaceutical form Suspension for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNAxalimogene filolisbac (formerly known as Lovaxin-C®)
    D.3.9.1CAS number n/a
    D.3.9.2Current sponsor codeADXS11-001
    D.3.9.3Other descriptive nameADXS11-001, Lm-LLO-E7, ADXS-HPV
    D.3.9.4EV Substance CodeSUB183748
    D.3.10 Strength
    D.3.10.1Concentration unit CFU/ml colony forming unit(s)/millilitre
    D.3.10.2Concentration typenot less then
    D.3.10.3Concentration number1000000000
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Yes
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Yes
    D.3.11.3.5.1CAT classification and reference numberEMA/357208/2016
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms Yes
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for infusion
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    High-risk locally advanced carcinoma of the cervix (HRLACC) following concurrent chemotherapy and radiation therapy.
    Carcinoma del cuello del útero avanzado localmente de alto riesgo (HRLACC, por su sigla en inglés) después de la terapia de radiación y quimioterapia simultáneas.
    E.1.1.1Medical condition in easily understood language
    HIGH RISK LOCALLY ADVANCED CERVICAL CANCER
    Cáncer de cuello uterino localmente avanzado de riesgo alto
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.1
    E.1.2Level LLT
    E.1.2Classification code 10008231
    E.1.2Term Cervical cancer recurrent
    E.1.2System Organ Class 100000004864
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.1
    E.1.2Level LLT
    E.1.2Classification code 10008229
    E.1.2Term Cervical cancer
    E.1.2System Organ Class 100000004864
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.1
    E.1.2Level LLT
    E.1.2Classification code 10008236
    E.1.2Term Cervical cancer stage IV
    E.1.2System Organ Class 100000004864
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.1
    E.1.2Level LLT
    E.1.2Classification code 10008235
    E.1.2Term Cervical cancer stage III
    E.1.2System Organ Class 100000004864
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.1
    E.1.2Level LLT
    E.1.2Classification code 10008234
    E.1.2Term Cervical cancer stage II
    E.1.2System Organ Class 100000004864
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.1
    E.1.2Level LLT
    E.1.2Classification code 10008233
    E.1.2Term Cervical cancer stage I
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To compare the disease free survival (DFS) of ADXS11-001 to placebo administered in the adjuvant setting following concurrent chemotherapy and radiotherapy (CCRT) administered with curative intent to subjects with high-risk locally advanced squamous, adenosquamous, or adenocarcinoma of the cervix (HRLACC).
    Comparar la supervivencia libre de enfermedad (DFS, por sus siglas en inglés) de ADXS11-001 administrado como adyuvante respecto a placebo después de la quimioterapia y radioterapia concurrentes (CCRT) administrados con intención curativa a pacientes con cáncer de cuello uterino (escamoso, adenoescamoso o adenocarcinoma) avanzado localmente de alto riesgo (HRLACC, por sus siglas en inglés).
    E.2.2Secondary objectives of the trial
    To determine and compare the frequency and severity of adverse events (AEs) as assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 for the regimens administered on this study.

    To evaluate the overall survival (OS) of ADXS11-001 administered in the adjuvant setting following definitive therapy of CCRT in subjects with HRLACC.
    Determinar y comparar la frecuencia y la gravedad de los eventos adversos (EA) para los regímenes administrados en este estudio, evaluados por los Criterios de Terminología Comunes para Eventos Adversos (CTCAE) del National Cancer Institute (NCA) versión 4.03.

    Evaluar la supervivencia global (OS, según sus siglas en inglés) de ADXS11-001 administrado como adyuvante después de la terapia definitiva de quimiorradioterapia (CCRT por sus siglas en inglés), en pacientes con HRLACC.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Subjects with:
    o Histological diagnosis of squamous cell, adenocarcinoma or adenosquamous carcinoma of the cervix who have undergone definitive therapy with a curative intent*

    Subjects may have:
    o Stage IB2, IIA2, IIB with any of the following pelvic lymph node metastases criteria:
    -Biopsy proven pelvic node(s)
    -2 or more positive nodes by MRI/CT ≥1.5 cm shortest dimension
    -2 or more positive pelvic nodes by PET with standard uptake value ≥2.5
    OR
    o All Stage IIIA, IIIB, IVA
    OR
    o Any FIGO stage with para-aortic lymph node metastases criteria (defined by 1 of the following):
    - Biopsy proven para-aortic node(s)
    - 1 or more positive para-aortic node(s) by MRI/CT >1.5 cm shortest dimension
    - 1 or more positive para-aortic node(s) by PET with SUV >2.5

    Subjects must have received definitive therapy with curative intent, which consist of at least 4 weeks treatment with cisplatin and a minimum of 40 Gy external beam radiation therapy (EBRT). NOTE: Brachytherapy is permitted.

    Subjects must be:
    o Age 18 years or older
    o GOG performance status 0 – 1
    o ANC ≥1000 x 109/L
    o Platelets ≥75 x 109/L
    o Bilirubin ≤1.5 x ULN
    o AST or ALT ≤2.5 x ULN
    o Serum creatinine or measured creatinine clearance ≤1.5 x ULN
    o Toxicities resulting from definitive therapy must resolve to ≤Grade 1 prior to randomization, with the exception of peripheral neuropathy (sensory and motor) which must resolve to ≤Grade 2.
    • Pacientes con:
    o Diagnóstico histológico de células escamosas, adenocarcinoma o carcinoma adenoescamoso de cuello de útero, que se hayan sometido a terapia definitiva con intención curativa*

    • Las pacientes pueden tener:
    o Estadios IB2, IIA2, IIB con cualquiera de los siguientes criterios de metástasis de ganglios linfáticos pélvicos:
    + Ganglio(s) en la pelvis confirmados mediante biopsia
    + 2 ganglios positivos o más según resonancia magnética (IRM)/ tomografía computada (TC) con ≥1.5 cm en su
    dimensión más corta
    + 2 ganglios pélvicos positivos o más según tomografía por emisión de positrones (TEP) con valor de absorción
    estándar (SUV, por su sigla en inglés) de ≥2.5
    O
    o Todas los estadios IIIA, IIIB, IVA
    O
    o Cualquier estadio FIGO con criterios de metástasis de ganglios linfáticos paraaórticos (definido por 1 de los siguientes):
    + Ganglio(s) paraaórtico(s) confirmado(s) mediante biopsia
    + 1 o más ganglios paraaórticos positivos segúnIRM/TC, con >1.5 cm en su dimensión más corta
    + 1 o más ganglios paraaórticos positivos según TEPcon SUV >2.5
    Las pacientes tienen que haber recibido terapia definitiva con intención curativa, la cual consiste de al menos 4 semanas de tratamiento con cisplatino y un mínimo de 40 Gy de radioterapia con rayos externos (EBRT, por sus siglas en inglés). NOTA: Se permite la braquiterapia.

    • Las pacientes deben tener:
    o 18 años de edad o más
    o estado funcional de GOG 0 – 1
    o ANC ≥1000 x 109/l
    o Plaquetas ≥75 x 109/l
    o Bilirrubina ≤1.5 x ULN
    o AST o ALT ≤2.5 x ULN
    o Creatinina en suero o aclaramiento de la creatinina medido ≤1.5 x ULN
    o Las toxicidades que resulten de la terapia definitiva deben resultar de ≤Grado 1 antes de la aleatorización, con excepción de neuropatías periféricas (sensorial y motriz) que debe resultar de ≤Grado 2.
    E.4Principal exclusion criteria
    - Subjects who have not achieved disease-free status (e.g. no evidence of measurable disease or non-measurable disease per RECIST 1.1) after completion of CCRT administered with curative intent.
    - Subjects with FIGO stage IVB
    - Histologies other than described above (neuroendocrine cancers are excluded)
    - Subjects who have undergone a previous hysterectomy defined as removal of the entire uterus or will have a hysterectomy as part of their initial cervical cancer therapy NOTE: Women who have had a partial/subtotal hysterectomy are eligible to participate in the study.
    - Has implanted medical device(s) that pose a high risk for colonization and/or cannot be easily removed (e.g., prosthetic joints, artificial heart valves, pacemakers, orthopedic screw(s), metal plate(s), bone graft(s), or other exogenous implant(s)). NOTE: More common devices and prosthetics which include arterial and venous stents, dental and breast implants and venous access devices (e.g. Port-a-Cath or Mediport) are permitted. Sponsor must be contacted prior to consenting any subject who has any other device and/or implant.
    - Who are receiving, plan, or anticipate on receiving PI3K or TNF�� inhibitors.
    - Has a contraindication (sensitivity or allergy) to trimethoprim/sulfamethoxazole and ampicillin.
    • Las pacientes que no hayan alcanzado el estado libre de enfermedad (por ejemplo, no hay evidencia de enfermedad medible o enfermedad no medible según RECIST 1.1) después de terminar la quimiorradioterapia administrada con intención curativa.
    • Pacientes con etapa FIGO IVB
    • Histologías distintas a las descritas anteriormente (se excluyen los cánceres neuroendocrinos)
    • Pacientes que se hayan sometido a una histerectomía previa definida como la extracción de todo el útero o que se vayan a realizar una histerectomía como parte de su terapia inicial contra el cáncer de cuello uterino. NOTA: Las mujeres que se hayan realizado una histerectomía parcial/subtotal son elegibles para participar en el estudio.
    • Pacientes que se hayan implantado dispositivos médicos que presenten un riesgo alto de colonización y/o no se puedan quitar fácilmente (por ejemplo, articulaciones protéticas, válvulas del corazón artificiales, marcapasos, tornillos ortopédicos, placas de metal, injertos de huesos u otros implantes exógenos). NOTA: Se permiten los dispositivos y prótesis más comunes que incluyen stents arteriales y venosos, implantes dentales y de mama y dispositivos de acceso a las venas (por ejemplo, Port-a-Cath o Mediport). Se debe contactar con el Promotor antes de pedir el consentimiento a una paciente que tenga otro tipo de dispositivo y/o implante.
    Quienes están recibiendo, planificando recibir o creen que recibirán inhibidores de PI3K o TNF��
    • Tiene una contraindicación (sensibilidad o alergia) a trimetoprim/sulfametoxazol y ampicilina.
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoint for this study is DFS measured from the time of randomization to recurrence or death.
    El objetivo primario de este estudio es la supervivencia sin enfermedad (DFS, por sus siglas en inglés) medida desde el momento de asignación aleatoria hasta la muerte o recidiva.
    E.5.1.1Timepoint(s) of evaluation of this end point
    PFS evaluated using RECIST 1.1 methodology every 3 months, beginning 3 months after the first dose, for the first 2 years and then every 6 months for up to a total of 5 years;
    Las pacientes que no hayan alcanzado el estado libre de enfermedad medible según RECIST 1.1 metodología de evaluación cada 3 meses, comenzando 3 meses después de la primera dosis los 2 primeros años y luego cada 6 meses por un total de 5 años.
    E.5.2Secondary end point(s)
    Secondary efficacy endpoint: OS (Overall survival)
    Objetivos secundarios de eficacia Supervivencia global (OS, por sus siglas en inglés).
    E.5.2.1Timepoint(s) of evaluation of this end point
    OS evaluated Approximately during 5 years
    Supervivencia global (OS) evaluado aproximádamente por 5 años
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned18
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA27
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Brazil
    Canada
    Chile
    Malaysia
    Mexico
    Netherlands
    Poland
    Romania
    Russian Federation
    Serbia
    Spain
    Taiwan
    Ukraine
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Última Visita del Último Paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years5
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 405
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 45
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male No
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state54
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 62
    F.4.2.2In the whole clinical trial 450
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    STANDARD CARE
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-05-08
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-04-21
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    P.Date of the global end of the trial2019-07-10
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 26 17:32:00 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA